Use of FCRN antagonists for treatment of generalized myasthenia gravis
US12240875B2 · kind B2 · utility
2Cited by
37References
21Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Dec 7, 2018 |
| Grant date | Mar 4, 2025 |
| Priority date | — |
| Expiry date | Feb 16, 2040 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Provided are novel methods of treating generalized myasthenia gravis in a subject. These methods generally comprise administering to the subject an effective amount of an isolated FcRn antagonist. In certain embodiments the FcRn antagonist binds to FcRn with increased affinity and reduced pH dependence relative to native Fc region.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.